Program
belumosudil
Also written as “Belumosudil”, “Belumosudil (KD025)” and “Belumosudil mesylate”.
Its studies are mostly in Bronchiolitis Obliterans Syndrome · Immune System Diseases · Scleroderma, Diffuse · Autoimmune Diseases · Psoriasis, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 256 open or running | phase 4since Sep 24, 2024 | Apr 2, 2014 | Jan 26, 2027phase 1 · NCT07726914 |
| BioNova Pharmaceuticals (Shanghai) | 10 open or running | phase 2since Jun 11, 2021 | Jun 11, 2021 | none ahead |
Also a collaborator on its studies: meiji-seika-pharma-co-ltd and quotient-sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 11 studies since Apr 2, 2014.
- Dec 11, 2020Phase 2 study in Scleroderma, DiffuseSanofi · NCT04680975 · 10 enrolled · United States
- Jan 13, 2021Early phase 1 study in Healthy VolunteersSanofi · NCT04735822 · 30 enrolled · United Kingdom
- Jun 11, 2021BioNova Pharmaceuticals (Shanghai)'s first study: phase 2 study in Bronchiolitis Obliterans SyndromeNew to BioNova Pharmaceuticals (Shanghai)BioNova Pharmaceuticals (Shanghai) · NCT04930562 · 30 enrolled · China
- Feb 2, 2022Phase 2 study in Bronchiolitis Obliterans SyndromeSanofi · NCT05305989 · 23 enrolled · United States
- Oct 3, 2022Phase 2 study in Bronchiolitis Obliterans SyndromeSanofi · NCT05567406
- Jun 15, 20233 phase 1 studies in Immune System DiseasesSanofi · NCT05918627, NCT05918614, NCT05918588
- Oct 7, 2023Phase 3 study in Lung Transplant RejectionSanofi · NCT06082037 · 180 planned · United States, Australia, Austria and more
- Nov 16, 2023Phase 3 study in Bronchiolitis Obliterans SyndromeSanofi · NCT06143891 · 260 enrolled · United States, Argentina, Australia and more
- Sep 24, 2024Phase 4 study in Bronchiolitis Obliterans SyndromeSanofi · NCT06616415 · 6 enrolled · China
- Jul 25, 2025Phase 2 study in Bronchiolitis Obliterans SyndromeSanofi · NCT07116031 · 37 planned · United States, Belgium, Canada and more
- Aug 14, 2025Phase 4 study in Bronchiolitis Obliterans SyndromeSanofi · NCT07135973 · 26 planned
- Jul 21, 2026Phase 1 study in Bronchiolitis Obliterans SyndromeSanofi · NCT07726914 · 58 planned
- Aug 4, 2026Phase 3 study in Bronchiolitis Obliterans SyndromeSanofi · NCT07771439 · 356 planned · Netherlands, Spain
- Nov 10, 2026Primary completion moved from 2026-09-28 to 2027-01-26Date moved laterphase 1 · +4 months · NCT07726914
Ahead
- Jan 26, 2027Primary completion: phase 1 study in Bronchiolitis Obliterans SyndromeSanofi · NCT07726914
- Aug 30, 2027Primary completion: phase 4 study in Bronchiolitis Obliterans SyndromeSanofi · NCT07135973
- Sep 25, 2028Primary completion: phase 2 study in Bronchiolitis Obliterans SyndromeSanofi · NCT07116031
- Sep 29, 2028Primary completion: phase 3 study in Bronchiolitis Obliterans SyndromeSanofi · NCT06143891
TargetBeta
“An orally bioavailable inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2; ROCK-II), ”NCIt, by rule
“Rho-associated protein kinase 2 inhibitor; Rho-associated protein kinase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| netarsudilrule | Alcon | phase 4 | 20 |
Studies
All 26 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07771439Bronchiolitis Obliterans Syndrome · Netherlands, Spain | 3 | Recruiting | Sanofi | Sep 14, 2029 | 356 |
| NCT07726914Bronchiolitis Obliterans Syndrome | 1 | Not yet recruiting | Sanofi | Jan 26, 2027 | 58 |
| NCT07135973Bronchiolitis Obliterans Syndrome | 4 | Not yet recruiting | Sanofi | Aug 30, 2027 | 26 |
| NCT07116031Bronchiolitis Obliterans Syndrome · United States, Belgium, Canada and more | 2 | Recruiting | Sanofi | Sep 25, 2028 | 37 |
| NCT06616415Bronchiolitis Obliterans Syndrome · China | 4 | Completed | Sanofi | May 12, 2026 | 6 |
| NCT06143891Bronchiolitis Obliterans Syndrome · United States, Argentina, Australia and more | 3 | Active, not recruiting | Sanofi | Sep 29, 2028 | 260 |
| NCT06082037Lung Transplant Rejection · United States, Australia, Austria and more | 3 | Recruiting | Sanofi | Jan 29, 2029 | 180 |
| NCT05918627Immune System Diseases · United States | 1 | Completed | Sanofi | Dec 9, 2009 | 32 |
| NCT05918614Immune System Diseases · United States | 1 | Completed | Sanofi | Jun 7, 2014 | 8 |
| NCT05918588Immune System Diseases · United States | 1 | Completed | Sanofi | Mar 6, 2014 | 32 |
| NCT05567406Bronchiolitis Obliterans Syndrome | 2 | Withdrawn | Sanofi | Aug 31, 2026 | 0 |
| NCT05305989Bronchiolitis Obliterans Syndrome · United States | 2 | Completed | Sanofi | Jun 6, 2024 | 23 |
| NCT04930562Bronchiolitis Obliterans Syndrome · China | 2 | Completed | BioNova Pharmaceuticals (Shanghai) | Jun 10, 2022 | 30 |
| NCT04735822Healthy Volunteers · United Kingdom | Early 1 | Completed | Sanofi | Sep 3, 2021 | 30 |
| NCT04680975Scleroderma, Diffuse · United States | 2 | Terminated | Sanofi | May 10, 2022 | 10 |
| NCT04166942Hepatic Impairment · United States | 1 | Completed | Sanofi | Jun 6, 2022 | 35 |
| NCT03907540Autoimmune Diseases · United Kingdom | 1 | Completed | Sanofi | May 20, 2019 | 5 |
| NCT03919799Scleroderma, Diffuse · United States | 2 | Terminated | Sanofi | Aug 9, 2022 | 36 |
| NCT03640481Bronchiolitis Obliterans Syndrome · United States | 2 | Terminated | Sanofi | Dec 11, 2023 | 159 |
| NCT03530995Autoimmune Diseases · United Kingdom | 1 | Completed | Sanofi | Feb 8, 2019 | 73 |
| NCT02852967Skin Diseases · United States | 2 | Completed | Sanofi | Feb 13, 2019 | 110 |
| NCT02841995Graft vs Host Disease · United States | 2 | Completed | Sanofi | May 12, 2022 | 54 |
| NCT02688647Idiopathic Pulmonary Fibrosis · United States | 2 | Completed | Sanofi | Apr 13, 2021 | 76 |
| NCT02557139Bioavailability · United Kingdom | 1 | Completed | Sanofi | Oct 12, 2015 | 23 |
| NCT02317627Psoriasis Vulgaris · United States | 2 | Completed | Sanofi | Mar 2016 | 38 |
| NCT02106195Psoriasis Vulgaris · United States | 2 | Completed | Sanofi | Sep 2014 | 8 |
How it is read
Names in the registry
- “Belumosudil”, 15 entries
- “Belumosudil (KD025)”, 3 entries
- “Belumosudil mesylate”, 3 entries
- “KD025”, 2 entries
- “Belumosudil 200 mg QD”, 1 entry
Conditions, from the studies’ own filings
- Bronchiolitis Obliterans Syndrome, 10 studies
- Immune System Diseases, 3 studies
- Scleroderma, Diffuse, 2 studies
- Autoimmune Diseases, 2 studies
- Psoriasis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.